Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
Hosted on MSN18h
Goldman Sachs Downgrades Moderna (MRNA)Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback